↓ Skip to main content

Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment

Overview of attention for article published in Alzheimer's Research & Therapy, December 2017
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
45 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Posterior atrophy predicts time to dementia in patients with amyloid-positive mild cognitive impairment
Published in
Alzheimer's Research & Therapy, December 2017
DOI 10.1186/s13195-017-0326-y
Pubmed ID
Authors

Jung-Min Pyun, Young Ho Park, Hang-Rai Kim, Jeewon Suh, Min Ju Kang, Beom Joon Kim, Young Chul Youn, Jae-Won Jang, SangYun Kim, the Alzheimer’s Disease Neuroimaging Initiative

Abstract

In patients with amyloid-positive mild cognitive impairment (MCI), neurodegenerative biomarkers such as medial temporal lobe atrophy (MTA) are useful to predict disease progression to dementia. Although posterior atrophy (PA) is a well-known neurodegenerative biomarker of Alzheimer's disease, little is known about PA as a predictor in patients with amyloid-positive MCI. We included 258 patients with amyloid-positive MCI with at least one follow-up visit, and who had low cerebrospinal fluid (CSF) β-amyloid1-42 concentration. Data were obtained from the Alzheimer's Disease Neuroimaging Initiative study. We assessed PA and MTA on magnetic resonance imaging (MRI) using visual rating scales and retrospectively determined progression to dementia during the follow-up period of up to 3 years (median 24 months). The Cox proportional hazards model was used to analyze hazard ratios (HRs) of PA and MTA for disease progression. Additionally, subjects were divided into four groups according to brain atrophy pattern (no atrophy, MTA only, PA only, both MTA and PA), and HRs for disease progression were compared with the no atrophy reference group. Analyses were conducted with and without adjustment for CSF phosphorylated tau181p (p-tau) and baseline demographics. A total of 123 patients (47.7%) showed MTA and 174 patients (67.4%) showed PA. Of the total cohort, 139 cases (53.9%) progressed to dementia. PA and MTA were associated with an increased risk for progression to dementia (HR 2.244, 95% confidence interval (CI) 1.497-3.364, and HR 1.682, 95% CI 1.203-2.352, respectively). In the analysis according to atrophy pattern, HR (95% CI) for progression was 2.998 (1.443-6.227) in the MTA only group, 3.126 (1.666-5.864) in the PA only group, and 3.814 (2.045-7.110) in both MTA and PA group. These results remained significant after adjustment. In patients with amyloid-positive MCI, PA could predict progression to dementia independently of MTA.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 45 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 45 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 16%
Student > Ph. D. Student 5 11%
Professor 4 9%
Student > Master 4 9%
Student > Bachelor 2 4%
Other 4 9%
Unknown 19 42%
Readers by discipline Count As %
Medicine and Dentistry 7 16%
Neuroscience 4 9%
Psychology 4 9%
Chemical Engineering 1 2%
Nursing and Health Professions 1 2%
Other 6 13%
Unknown 22 49%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 January 2018.
All research outputs
#19,968,026
of 25,402,889 outputs
Outputs from Alzheimer's Research & Therapy
#1,385
of 1,469 outputs
Outputs of similar age
#320,865
of 444,175 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#21
of 23 outputs
Altmetric has tracked 25,402,889 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,469 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.6. This one is in the 4th percentile – i.e., 4% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 444,175 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.